AR-9281
CAS No. 913548-29-5
AR-9281 ( APAU )
Catalog No. M22923 CAS No. 913548-29-5
AR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 73 | In Stock |
|
5MG | 105 | In Stock |
|
10MG | 158 | In Stock |
|
25MG | 284 | In Stock |
|
50MG | 428 | In Stock |
|
100MG | 626 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAR-9281
-
NoteResearch use only, not for human use.
-
Brief DescriptionAR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes.
-
DescriptionAR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes.
-
SynonymsAPAU
-
PathwayOthers
-
TargetOther Targets
-
Recptors-EH
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number913548-29-5
-
Formula Weight319.44
-
Molecular FormulaC18H29N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:25 mg/mL (78.26 mM; Need ultrasonic)
-
SMILESCC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen D, et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol. 2012 Mar;52(3):319-28.
molnova catalog
related products
-
TAS-102
TAS-102 is an investigational drug candidate for metastatic colorectal Y. It contains trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
-
Erigeside C
Erigeside C is a natural product of Erigeron, Asteraceae. Erigeside C can be used as a reference standard.
-
Fibrinopeptide B, hu...
Fibrinopeptide B (FPB) is produced during the cleavage of fibrinogen, by thrombin, to fibrin monomer.